Horizon Discovery Group, a Cambridge-based biotech backed by DFJ Esprit and Roche Venture Fund among others, has raised £68.6m for its IPO on the AIM of the London Stock Exchange.
Deal includes the restructuring of around €60m in debt and the injection of fresh funds, as well as managerial support
Deal is in line with a generational change in ownership of Tätab, which was established in 1963
A highlight of deal processes underway and involving PE, either on the buy- or sell-side, across Europe
In his new role, Livio Zanotelli will focus on identifying new investment opportunities across Italy